According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
A number of other brokerages have also commented on VTVT. HC Wainwright initiated coverage on vTv Therapeutics in a research report on Monday, September 26th. They issued a buy rating and a $13.00 price objective on the stock. Canaccord Genuity reiterated a buy rating and issued a $15.00 price objective on shares of vTv Therapeutics in a research report on Friday, August 19th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. vTv Therapeutics currently has a consensus rating of Buy and a consensus target price of $16.00.
vTv Therapeutics (NASDAQ:VTVT) opened at 6.99 on Wednesday. The company’s 50-day moving average price is $6.57 and its 200 day moving average price is $5.94. The firm’s market capitalization is $67.73 million. vTv Therapeutics has a 52-week low of $4.84 and a 52-week high of $8.22.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. Equities analysts predict that vTv Therapeutics will post ($1.61) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Investment Management LLC increased its stake in shares of vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock valued at $161,000 after buying an additional 5,596 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock valued at $180,000 after buying an additional 822 shares during the last quarter. Kennedy Capital Management Inc. acquired a new stake in shares of vTv Therapeutics during the first quarter valued at approximately $282,000. State Street Corp increased its stake in shares of vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock valued at $316,000 after buying an additional 6,000 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock valued at $559,000 after buying an additional 18,112 shares during the last quarter. Institutional investors and hedge funds own 12.84% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.